Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States. (Q39844710)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

main subject

United States of America

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Deepa Lalla

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Melissa Brammer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Quan Doan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Kevin Knopf

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

English

0 references

publication date

23 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

5575-5583

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20734398%20AND%20SRC:MED&resulttype=core&format=json

Work absence after breast cancer diagnosis: a population-based study

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Trastuzumab: a pharmacoeconomic review of its use in early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Quantifying errors without random sampling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

HER-2 testing in breast cancer using parallel tissue-based methods

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Do we need HER-2/neu testing for all patients with primary breast carcinoma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Histopathologic characteristics predicting HER-2/neu amplification in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Patient time costs associated with cancer care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Resource use and costs associated with different states of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Productivity costs of cancer mortality in the United States: 2000-2020

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Long-term survival of women with breast cancer in New South Wales

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Excess mortality from breast cancer 20 years after diagnosis when life expectancy is normal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Evaluation of trends in the cost of initial cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Future supply and demand for oncologists : challenges to assuring access to oncology services

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

How should we value lives lost to cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Absenteeism from work: the experience of employed breast and prostate cancer patients in the months following diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Cancer survivors and unemployment: a meta-analysis and meta-regression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021

Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25347

7 January 2021